Hence, SCFAs act at different levels by decreasing the inflammatory state that reduces insulin resistance, increasing the protective glucagon-like peptide-1 (GLP-1) secretion that stimulates insulin release and improving β-cell function [123]. The gene discussed is GCG; the disease is Insulin resistance.